EFA involved in U-BIOPRED project on understanding severe asthma better
EFA is a partner in an EU research project on severe asthma the U-BIOPRED (Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes). The five year project is part of the so-called Innovative Medicines Initiative (IMI), a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA), which funds projects withthe aim of combating causes of delay in development of medicines.
U-BIOPRED brings together patients organisations, bio-pharmaceuticals enterprises, small and medium enterprises, the European Medicine Agency, and academic institutions. It aims at improving understanding of severe asthma, its diversity, and the history and progression of the disease. Better understanding will help to develop more targeted treatments for people with severe asthma, which fits perfectly with the global theme of WAD: launch of a campaign by Global Initiative of Asthma to reduce asthma hospitalizations by 50%.
EFA is contributing to U-BIOPRED and representing patients within this project together with Asthma UK and Netherlands Asthma Foundation through involvement in consensus, ethics and dissemination and training work packages and by giving opportunities for members involvement in providing patient perspective. Stay tune on the progress in this newsletter and the Project website will be available this spring. Breda Flood, EFA leader in U-BIOPRED